Prostate-specific antigen (PSA) is a protein produced by both normal and cancerous cells in the prostate gland. It is primarily measured through a blood test, where normal levels are typically found ...

Many men with low levels could be spared from invasive procedures and frequent testing ...

Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on disease progression. Among patients with intermediate-risk prostate cancer, ...

Prostate cancer screening is essential for early detection, especially in high-risk groups like men over 50, African Americans, and those with a family history. Routine screening, including PSA tests ...

Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

PSA and Ki-67 tumour markers may identify high-risk metastatic castration-sensitive prostate cancer and inform treatment ...

This article was reviewed by Darragh O’Carroll, MD. Prostate-specific antigen (PSA) is a term you’ll probably become familiar with once you start getting screened regularly for prostate cancer ...

* Higher PSA levels at 65-69 linked to greater prostate cancer mortality after 70 * 80% of prostate cancer deaths after age 70 occurred in men with PSA (and) #8805;2.0 ng/mL //at 65-69 * Low PSA ...

PSA levels can be elevated for reasons other than cancer, such as an enlarged or inflamed prostate. False positive and false negative PSA test results are possible. The American Cancer Society does ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." IF YOU’VE NEVER had a prostate cancer screening, you may worry that it will be embarrassing and ...

Medicare covers one annual prostate-specific antigen (PSA) test for people with prostates if they meet the eligibility guidelines and the test is medically necessary. Medicare typically covers one ...

Achieving a PSA nadir of less than 0.2 ng/mL is needed for optimal mCSPC outcomes. For real-world patients with metastatic castration-sensitive prostate cancer (mCSPC), reaching a PSA nadir less than ...